Jaypirca was shown to work in most adults with previously treated CLL
of adults with CLL (78 out of 108) saw their cancer shrink and stop spreading while taking Jaypirca
In a clinical trial that measured the number of people who responded to treatment and how long the response lasted:
- For those who saw their cancer shrink and stop spreading, their response lasted a median* of 12.2 months
*Median is the middle number in a range of numbers.
SELECT SAFETY INFORMATION
Warnings - Jaypirca may cause serious side effects, including:
Bleeding problems (hemorrhage). Bleeding problems can happen during treatment with Jaypirca. They can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. Tell your doctor if you have any signs or symptoms of bleeding, including:
- blood in your stools or black stools (looks like tar)
- pink or brown urine
- unexpected bleeding, or bleeding that is severe or you cannot control
- vomit blood or vomit blood that looks like coffee grinds
- cough up blood or blood clots
- increased bruising
- changes in your speech
- headache that lasts a long time
In a clinical trial for people with previously treated CLL, Jaypirca started working quickly. Some saw their cancer reduce in size and stop spreading approximately 7 weeks after starting treatment.
In a clinical trial of Jaypirca, the median time for the cancer to shrink and stop spreading with treatment was 3.7 months, ranging from 1.7 months at the lowest to 27.9 months at the highest. Median is the middle number in a range of numbers ordered from lowest to highest.
Jaypirca was studied in a clinical trial that included adults with CLL who had received at least two treatments, including a Bruton's tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.
Jaypirca was studied in 108 adults with previously treated CLL
All people in the study were treated with a prior BTK inhibitor and a BCL-2 inhibitor
Trial evaluated response to treatment and how long the response lasted (a response means their cancer shrank and stopped spreading)
Trial participants took Jaypirca once daily until their disease got worse or they were no longer able to tolerate treatment
Learn about taking Jaypirca and possible side effects